MA35437B1 - Proteines de fusion pour le traitement de troubles du metabolisme - Google Patents

Proteines de fusion pour le traitement de troubles du metabolisme

Info

Publication number
MA35437B1
MA35437B1 MA36824A MA36824A MA35437B1 MA 35437 B1 MA35437 B1 MA 35437B1 MA 36824 A MA36824 A MA 36824A MA 36824 A MA36824 A MA 36824A MA 35437 B1 MA35437 B1 MA 35437B1
Authority
MA
Morocco
Prior art keywords
fusion proteins
metabolic disorders
treatment
fgf21
proteins
Prior art date
Application number
MA36824A
Other languages
English (en)
Inventor
Brian R Boettcher
Shari L Caplan
Douglas S Daniels
Norio Hamamatsu
Stuart Licht
Stephen Craig Weldon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA35437B1 publication Critical patent/MA35437B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'identification de protéines de fusion comprenant des variants de polypeptides et de protéines du facteur de croissance des fibroblastes 21 (fgf21) présentant des propriétés pharmaceutiques améliorées. L'invention concerne également des procédés de traitement de troubles associés au fgf21, y compris des troubles du métabolisme
MA36824A 2011-09-26 2014-03-13 Proteines de fusion pour le traitement de troubles du metabolisme MA35437B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161539280P 2011-09-26 2011-09-26
PCT/US2012/057384 WO2013049247A1 (fr) 2011-09-26 2012-09-26 Protéines de fusion pour le traitement de troubles du métabolisme

Publications (1)

Publication Number Publication Date
MA35437B1 true MA35437B1 (fr) 2014-09-01

Family

ID=46970456

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36824A MA35437B1 (fr) 2011-09-26 2014-03-13 Proteines de fusion pour le traitement de troubles du metabolisme

Country Status (41)

Country Link
US (6) US9006400B2 (fr)
EP (2) EP2760475B1 (fr)
JP (4) JP6186361B2 (fr)
KR (1) KR102085605B1 (fr)
CN (2) CN107266579B (fr)
AP (1) AP2014007543A0 (fr)
AR (2) AR088044A1 (fr)
AU (1) AU2012316052A1 (fr)
BR (1) BR112014007069B1 (fr)
CA (1) CA2849464C (fr)
CL (2) CL2014000736A1 (fr)
CO (1) CO6920257A2 (fr)
CR (1) CR20140140A (fr)
CU (2) CU24314B1 (fr)
CY (2) CY1120928T1 (fr)
DK (2) DK3321276T3 (fr)
EA (1) EA039633B1 (fr)
ES (2) ES2895080T3 (fr)
GT (1) GT201400055A (fr)
HR (2) HRP20181558T1 (fr)
HU (2) HUE039857T2 (fr)
IL (1) IL231533B (fr)
IN (1) IN2014DN02043A (fr)
JO (1) JO3476B1 (fr)
LT (2) LT3321276T (fr)
MA (1) MA35437B1 (fr)
MX (1) MX350273B (fr)
MY (1) MY166059A (fr)
PE (2) PE20141551A1 (fr)
PL (2) PL3321276T3 (fr)
PT (2) PT3321276T (fr)
RS (2) RS57868B1 (fr)
SG (2) SG10201602339XA (fr)
SI (2) SI2760475T1 (fr)
SM (1) SMT202100595T1 (fr)
TN (1) TN2014000109A1 (fr)
TW (1) TWI593708B (fr)
UA (1) UA113856C2 (fr)
UY (2) UY34346A (fr)
WO (1) WO2013049247A1 (fr)
ZA (1) ZA201401700B (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299015B2 (en) 2006-07-25 2012-10-30 Lipoxen Technologies Limited Derivatisation of granulocyte colony-stimulating factor
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
WO2012019168A2 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucléiques modifiés et leurs procédés d'utilisation
EP2625189B1 (fr) 2010-10-01 2018-06-27 ModernaTX, Inc. Synthèse d'acides nucléiques et méthodes d'utilisation associées
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN105601748B (zh) 2011-07-01 2021-08-27 恩格姆生物制药公司 用于代谢病症和疾病治疗的组合物、应用和方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (fr) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Nucleoside, nucleotide, et compositions d'acide nucleique modifies
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151665A2 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés destinés à la production de protéines associées à une maladie humaine
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2915851T3 (es) 2012-12-27 2022-06-27 Ngm Biopharmaceuticals Inc Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
EP3052521A1 (fr) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
EP3057605A1 (fr) 2013-10-18 2016-08-24 Novartis AG Méthodes de traitement du diabete et de troubles associés
CA2927592C (fr) 2013-10-28 2020-08-18 Ngm Biopharmaceuticals, Inc. Variants de fgf-19 pour le traitement d'un cancer ou d'une tumeur fgf-19-dependant
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
WO2015183890A2 (fr) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Méthodes et compositions pour le traitement de maladies et de troubles métaboliques
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
RU2729161C2 (ru) * 2014-10-23 2020-08-04 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
US11236159B2 (en) * 2015-08-03 2022-02-01 Novartis Ag Methods of treating FGF21-associated disorders
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
MX2018014256A (es) * 2016-05-20 2019-08-16 Harvard College Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
MX2018014475A (es) * 2016-05-25 2019-05-23 Univ Texas Métodos y composiciones para el tratamiento de trastornos secretorios.
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN106317226B (zh) * 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CA3034399A1 (fr) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methodes de traitement de cancers et de tumeurs a mediation assuree par le facteur de croissance des fibroblastes 19
BR112019012693A2 (pt) 2016-12-22 2019-11-19 Sanofi combinações de composto de fgf21/agonista do glp-1r com razão de atividade otimizada
WO2018166461A1 (fr) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Protéines de fusion à double cible comprenant la partie fc d'une immunoglobuline
CN107050429B (zh) * 2017-04-01 2020-12-15 杭州生物医药创新研究中心 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用
MX2019013210A (es) * 2017-05-05 2020-07-20 Trefoil Therapeutics Inc Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos.
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
WO2019119673A1 (fr) 2017-12-19 2019-06-27 北京吉源生物科技有限公司 Cellule souche modifiée par deux gènes et utilisation de cette dernière
WO2019123427A1 (fr) * 2017-12-22 2019-06-27 Novartis Ag Procédés de traitement de troubles métaboliques avec des variants de fgf21
AU2019218147B2 (en) 2018-02-08 2023-06-08 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
WO2019243557A1 (fr) * 2018-06-21 2019-12-26 Sanofi Combinaisons associant le composé fgf21 et un agoniste du glp-1r selon un rapport optimisant leur activité
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
EP3736574A1 (fr) * 2019-05-07 2020-11-11 Atlas Antibodies AB Formulation contenant polypeptides de fusion marques par un isotope
CN111944055B (zh) 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
WO2021050789A1 (fr) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Protéines de fusion de ca2-il15 pour une régulation accordable
US20230060422A1 (en) 2019-12-20 2023-03-02 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
JP6924291B2 (ja) 2020-01-21 2021-08-25 シャープ株式会社 端末装置、方法、および、集積回路
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
US20230265152A1 (en) * 2020-07-02 2023-08-24 Sanofi Glp-1r agonist / fgf21 fusion proteins
WO2022101853A1 (fr) 2020-11-16 2022-05-19 Novartis Ag Procédé de détermination de la fibrose hépatique
CN113265007B (zh) * 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
CN115286705B (zh) * 2021-12-30 2024-05-10 长江大学 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用
WO2023245543A1 (fr) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Utilisations de protéines de fusion fgf21
WO2024123812A1 (fr) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Protéines de fusion pour le traitement de maladies cardiométaboliques
WO2025108432A1 (fr) * 2023-11-23 2025-05-30 Therorna Shanghai Co., Ltd. Arn circulaire codant pour fgf21 et son utilisation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
ATE106249T1 (de) 1987-11-05 1994-06-15 Hybritech Inc Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
EP2163626A1 (fr) 1999-11-18 2010-03-17 Novartis Vaccines and Diagnostics, Inc. Gène humain fgf-21 et produits d'expression génique
EP1244708B8 (fr) 1999-12-23 2007-03-07 ZymoGenetics, Inc. Methode destinee a traiter l'inflammation
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
WO2005037867A1 (fr) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Modification de demi-vies seriques de proteines de fusion fc par mutagenese de positions 250, 314 et/ou 428 de la region constante de la chaine lourde des immunoglobulines
EP2270163A1 (fr) * 2003-12-10 2011-01-05 Eli Lilly and Company Mutéines du facteur de croissance des fibroblastes
EP2194064A1 (fr) * 2004-05-13 2010-06-09 Eli Lilly & Company Protéines de fusion FGF-21
KR100854198B1 (ko) * 2004-09-02 2008-08-26 일라이 릴리 앤드 캄파니 섬유아세포 성장 인자 21의 뮤테인
EP1846019A2 (fr) 2005-01-21 2007-10-24 Eli Lilly And Company Methode de traitement de maladie cardio-vasculaire
US8034770B2 (en) * 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
WO2010048582A1 (fr) 2008-10-24 2010-04-29 Irm Llc Pyrroline-carboxy-lysine produite par biosynthèse et modifications de protéines spécifiques de site obtenues par une dérivatisation chimique de pyrroline-carboxy-lysine et de résidus de pyrrolysine
WO2010129600A2 (fr) 2009-05-05 2010-11-11 Amgen Inc. Mutants de fgf21 et leurs utilisations
WO2010129503A1 (fr) * 2009-05-05 2010-11-11 Amgen Inc. Mutants de fgf21 et leurs utilisations
MX2011013903A (es) * 2009-06-17 2012-05-08 Amgen Inc Polipeptidos quimericos y usos de los mismos.
BR112012017164A2 (pt) 2009-12-22 2019-09-24 Novartis Ag proteína de fusão de região constante de anticorpo-cd47 tetravalente
DE102010038140B4 (de) * 2010-10-13 2020-06-18 Hettich-Heinze Gmbh & Co. Kg Beschlag für eine Schiebetür
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
TWI593708B (zh) * 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途

Also Published As

Publication number Publication date
CU20150171A7 (es) 2016-07-29
CU20140034A7 (es) 2014-08-28
CU24206B1 (es) 2016-10-28
HUE055584T2 (hu) 2021-12-28
SMT202100595T1 (it) 2022-01-10
CU24314B1 (es) 2018-02-08
AP2014007543A0 (en) 2014-03-31
RS62341B1 (sr) 2021-10-29
JP2018023370A (ja) 2018-02-15
US12527841B2 (en) 2026-01-20
TW201326213A (zh) 2013-07-01
EP2760475A1 (fr) 2014-08-06
PE20141551A1 (es) 2014-10-26
CO6920257A2 (es) 2014-04-10
CL2014000736A1 (es) 2014-10-03
JP6186361B2 (ja) 2017-08-23
NZ622998A (en) 2016-07-29
PT3321276T (pt) 2021-10-27
CY1120928T1 (el) 2019-12-11
UY39119A (es) 2021-04-30
MX350273B (es) 2017-08-31
CN107266579A (zh) 2017-10-20
GT201400055A (es) 2017-09-28
US9266935B2 (en) 2016-02-23
PL2760475T3 (pl) 2018-11-30
US20210386824A1 (en) 2021-12-16
IL231533B (en) 2018-06-28
PT2760475T (pt) 2018-10-25
JP2014534172A (ja) 2014-12-18
CL2016002215A1 (es) 2016-10-28
CN107266579B (zh) 2022-07-12
EA039633B1 (ru) 2022-02-18
HRP20211575T1 (hr) 2022-02-04
JP6567613B2 (ja) 2019-08-28
TWI593708B (zh) 2017-08-01
LT3321276T (lt) 2021-11-10
HRP20181558T1 (hr) 2018-11-30
BR112014007069A2 (pt) 2017-03-28
DK2760475T3 (en) 2018-10-15
US11944664B2 (en) 2024-04-02
AR088044A1 (es) 2014-05-07
US20240261372A1 (en) 2024-08-08
SG10201602339XA (en) 2016-05-30
CY1124697T1 (el) 2022-07-22
ES2689762T3 (es) 2018-11-15
ES2895080T3 (es) 2022-02-17
EP2760475B1 (fr) 2018-07-04
US20160193297A1 (en) 2016-07-07
CN103945871A (zh) 2014-07-23
IN2014DN02043A (fr) 2015-05-15
HK1251238A1 (en) 2019-01-25
US20180369332A1 (en) 2018-12-27
AU2012316052A1 (en) 2014-04-17
RS57868B1 (sr) 2018-12-31
BR112014007069B1 (pt) 2020-12-15
WO2013049247A1 (fr) 2013-04-04
ZA201401700B (en) 2015-01-28
SG11201400538QA (en) 2014-06-27
HUE039857T2 (hu) 2019-02-28
JO3476B1 (ar) 2020-07-05
IL231533A0 (en) 2014-04-30
DK3321276T3 (da) 2021-10-25
US9006400B2 (en) 2015-04-14
CN103945871B (zh) 2017-04-26
EP3321276B1 (fr) 2021-07-28
KR20140069250A (ko) 2014-06-09
US20150166622A1 (en) 2015-06-18
MX2014003677A (es) 2014-04-30
UY34346A (es) 2013-04-30
US20130079500A1 (en) 2013-03-28
EA201490695A1 (ru) 2015-10-30
LT2760475T (lt) 2018-10-25
PE20181159A1 (es) 2018-07-19
JP2020007314A (ja) 2020-01-16
US10076554B2 (en) 2018-09-18
PL3321276T3 (pl) 2022-01-17
EP3321276A2 (fr) 2018-05-16
EP3321276A3 (fr) 2018-06-20
SI3321276T1 (sl) 2021-11-30
CA2849464C (fr) 2024-01-30
CA2849464A1 (fr) 2013-04-04
KR102085605B1 (ko) 2020-03-06
UA113856C2 (xx) 2017-03-27
JP7339372B2 (ja) 2023-09-05
MY166059A (en) 2018-05-22
TN2014000109A1 (en) 2015-07-01
CR20140140A (es) 2014-07-15
US11129874B2 (en) 2021-09-28
AR123908A2 (es) 2023-01-25
JP2022058546A (ja) 2022-04-12
SI2760475T1 (sl) 2018-10-30

Similar Documents

Publication Publication Date Title
MA35437B1 (fr) Proteines de fusion pour le traitement de troubles du metabolisme
MA35507B1 (fr) Protéines à double fonction pour le traitement de troubles du métabolisme
MA34710B1 (fr) Procede de traitement des troubles associes au fgf21
PH12018502451A1 (en) Brain delivery protein
MY183712A (en) Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
MA37963A1 (fr) Protéines de fusion pour traiter un syndrome métabolique
UA104626C2 (ru) Анти-vegf антитело и его применение
EP2563794A4 (fr) Inhibiteurs de l'activité protéine tyrosine kinase et leurs applications au traitement de troubles ophtalmiques
MX2018004041A (es) Tratamiento de trastornos de acidos biliares.
WO2019016597A3 (fr) Protéines synthétiques et leurs utilisations thérapeutiques
TN2013000211A1 (en) Methods of treating fgf 21- associated disorders
MA37640A1 (fr) Protéines du facteur de croissance des fibroblastes 21
TH145764A (th) วิธีการสำหรับการบำบัดความผิดปกติที่เกี่ยวข้องกับ fgf21
TN2010000348A1 (en) Methods and compositions using klotho-fgf fusion polypeptides